12/18/2023 0 Comments IdarucizumabThe primary end point of this study was the maximum percent reversal of anticoagulation by dabigatran, as measured by dilute thrombin time and ecarin clotting time. All patients were administered 5g of intravenous idarucizumab total, given as two 2.5mg bolus infusions, and blood samples were collected at various time points from baseline to 24 hours after the second bolus. This interim analysis included patients from 35 countries taking dabigatran who either required rapid reversal of anticoagulation for life-threatening bleeding, or who required it for urgent surgery or invasive procedures (n = 90). In-Depth : The RE-VERSE AD study aimed to determine if idarucizumab, a monoclonal antibody that binds and neutralizes thrombin-bound dabigatran, was effective in reversing dabigatran’s anticoagulant effects.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |